Treatment of acute postoperative anemia with recombinant human erythropoietin.
Risks inherent in the administration of blood products have increased efforts to avoid homologous transfusion. Although this has increased interest in autologous transfusion and intraoperative salvage, little attention has been focused on efforts to enhance endogenous erythropoiesis as a method of minimizing exposure to homologous blood. Recombinant human erythropoietin (rHuEPO) has been shown to enhance erythropoiesis. The purpose of this study is to evaluate the effect of rHuEPO, administered postoperatively, on a model of acute blood loss. Eleven adult male baboons were randomized into two groups. All animals underwent a laparotomy and an exchange transfusion, with 6% hetastarch, to a final hematocrit of 15%. Group I (N = 6) received 1,000 units/kg of recombinant human erythropoietin daily for the first 14 postoperative days. Group II (N = 5) received an equivalent volume of placebo. All animals were given supplemental vitamin B12, folate and 200% of shed iron, as iron dextran IV, after exchange transfusion. Response was observed for a period of 35 days. All animals survived the protocol. There were no adverse reactions to rHuEPO or surgical complications. The hematocrits were similar between groups at baseline and after exchange transfusion. The maximal rate of erythropoiesis was significantly faster in the rHuEPO group (2.1 vs. 1.3%/day; p less than 0.01). The time required to return to hematocrits of 30% (9.9 vs. 17.4 days, p less than 0.001) and to baseline hematocrits (11.9 vs. 32.1 days, p less than 0.01) were both significantly shorter in the rHuEPO group. The data show that rHuEPO accelerates the recovery from anemia in the postoperative setting. Acceleration of erythropoiesis represents another alternative to homologous transfusion.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Surgery, Michael Reese Hospital and Medical Center, Chicago, IL 60616.
E A
EA
Levine
A L
AL
Rosen
L R
LR
Sehgal
S A
SA
Gould
J C
JC
Egrie
H L
HL
Sehgal
G S
GS
Moss
D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D001706:Biopsy; D001772:Blood Cell Count / Q000187:drug effects; D001853:Bone Marrow / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D004909:Erythrocyte Indices / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005078:Exchange Transfusion, Whole Blood; D006400:Hematocrit; D006801:Humans; D010215:Papio; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D011994:Recombinant Proteins; D004921:Erythropoietin